Patents by Inventor Aaron Paul YAMNIUK

Aaron Paul YAMNIUK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11919962
    Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: March 5, 2024
    Assignee: Bristol Myers-Squibb Company
    Inventors: Aaron Paul Yamniuk, Scott Ronald Brodeur, Ekaterina Deyanova, Richard Yu-Cheng Huang, Yun Wang, Alfred Robert Langish, Guodong Chen, Stephen Michael Carl, Hong Shen, Achal Mukundrao Pashine, Lin Hui Su
  • Publication number: 20230295310
    Abstract: Anti-CD3 antibodies for use in the diagnosis or treatment of hyperproliferative or autoimmune disorders methods of using the same for detecting and/or treating a hyperproliferative or autoimmune disorders.
    Type: Application
    Filed: March 20, 2023
    Publication date: September 21, 2023
    Applicant: AbCellera Biologics Inc.
    Inventors: Lindsay DEVORKIN, Aaron Paul YAMNIUK, Bryan Crawford BARNHART, Wei WEI, Kevin HEYRIES, Harveer DHUPAR, Sherie DUNCAN, Timothy M. JACOBS
  • Publication number: 20230140384
    Abstract: Provided herein are agonist antibodies that bind to human CD40 with enhanced agonist activity. Such antibodies comprise Fc regions with amino acid substitutions that enhance the agonist activity of the antibody compared with a similar IgG1 antibody. Such substitutions include sequence variants in the IgG2 hinge region and sequence variants that enhance hexamerization of the antibodies. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Application
    Filed: March 8, 2021
    Publication date: May 4, 2023
    Inventors: Arvind RAJPAL, Aaron Paul YAMNIUK, Pavel STROP, Bryan C. BARNHART, Feng WANG
  • Publication number: 20220220220
    Abstract: The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.
    Type: Application
    Filed: January 7, 2022
    Publication date: July 14, 2022
    Inventors: Joseph M. Luettgen, Lumelle Schneeweis, Ginger Chao Rakestraw, Christina Terragni, Andrew Karl Dilger, Jason Robert Pinckney, Steven Sheriff, Kevin Kish, Yongmi An, William R. Ewing, Stanley Richard Krystek, JR., Aaron Paul Yamniuk
  • Publication number: 20220017627
    Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.
    Type: Application
    Filed: April 16, 2021
    Publication date: January 20, 2022
    Inventors: Aaron Paul Yamniuk, Scott Ronald Brodeur, Ekaterina Deyanova, Richard Yu-Cheng Huang, Yun Wang, Alfred Robert Langish, Guodong Chen, Stephen Michael Carl, Hong Shen, Achal Mukundrao Pashine, Lin Hui Su
  • Patent number: 11008395
    Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: May 18, 2021
    Assignee: Bristol Myers-Squibb Company
    Inventors: Aaron Paul Yamniuk, Scott Ronald Brodeur, Ekaterina Deyanova, Richard Yu-Cheng Huang, Yun Wang, Alfred Robert Langish, Guodong Chen, Stephen Michael Carl, Hong Shen, Achal Mukundrao Pashine, Lin Hui Su
  • Publication number: 20200231687
    Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.
    Type: Application
    Filed: January 21, 2020
    Publication date: July 23, 2020
    Applicant: Bristol Myers-Squibb Company
    Inventors: Aaron Paul YAMNIUK, Scott Ronald BRODEUR, Ekaterina DEYANOVA, Richard Yu-Cheng HUANG, Yun WANG, Alfred Robert LANGISH, Guodong CHEN, Stephen Michael CARL, Hong SHEN, Achal Mukundrao PASHINE, Lin Hui SU